PRODUCTSNEXLETOL^®, NEXLIZET^®, ENBUMYST^®

NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) are oral, non-statin therapies FDA approved to lower low density lipoprotein cholesterol (LDL-C) and reduce the risk of myocardial infarction and coronary revascularization in patients who unable to take recommended statin therapy or need more LDL-C lowering than a statin alone can provide. The products, which act upstream of statins, were initially FDA approved in February 2020 and subsequently received expanded indications in March 2024 to include cardiovascular risk reduction and LDL-C lowering in both primary and secondary prevention patients.

ENBUMYST® (bumetanide nasal spray) is an Intranasal loop diuretic that received FDA approval in September 2025 and is indicated for the treatment of edema associated with congestive heart failure, hepatic and renal disease, including nephrotic syndrome in adults.

Background

In December 2024, HealthCare Royalty and Athyrium Capital Management collectively provided Esperion Therapeutics with a credit facility of $150 million (with HealthCare Royalty contributing $50 million). The credit facility was part of a broader refinancing of a portion of outstanding obligations under the company’s $265 million in 4.00% Convertible Senior Subordinated Notes due November 2025.

In April 2026, Healthcare Royalty provided $25 million in acquisition financing to Esperion through an upsizing of the original senior secured credit facility Esperion used the proceeds, along with another related financing, to complete its $75 million strategic acquisition of Corstasis, broadening Esperion’s cardiovascular franchise with the addition of ENBUMYST®